Drug Type Biosimilar, Monoclonal antibody |
Synonyms Denosumab Biosimilar (Outlook Therapeutics, Inc.), 地舒单抗生物类似药(Outlook Therapeutics, Inc.), ONS-4010 |
Target |
Action inhibitors |
Mechanism RANKL inhibitors(Tumor necrosis factor ligand superfamily member 11 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |


| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Bone metastases | Preclinical | United States | 04 May 2016 | |
| Giant Cell Tumor of Bone | Preclinical | United States | 04 May 2016 | |
| Osteoporosis | Preclinical | United States | 04 May 2016 |






